rcc
MSD announce new data from advanced renal cell carcinoma trial
June 8, 2021Manufacturing and Production MSD, rcc
Merk (MSD) has announced positive data from its Phase III Clear/Keynote-581 trial on Keytruda (pembrolizumab) plus Lenvima (lenvatinib), and Lenvima …
FDA approves AVEO’s kidney cancer treatment
March 11, 2021Aveo, FDA, Kidney cancer, fotivda, rcc
The FDA has approved AVEO Oncology’s FOTIVDA drug for the treatment of adults with relapsed or refractory advanced renal cell …
MSD’s Keytruda combo therapy significantly improves survival in advanced renal cell carcinoma
February 18, 2019Sales and Marketing Cancer, MSD, Merck Sutent, Pfizer, inlyta, keytruda, oncology, rcc, renal cell carcinoma
Merck & Co’s Keytruda (pembrolizumab) in combination with Pfizer’s Inlyta (axitinib) significantly extended the lives of those with advanced renal …
Scotland approves first-line treatment for advanced kidney cancer
July 9, 2018Sales and Marketing Cancer, Scotland, fotivda, rcc, tivozanib
The Scottish Medicines Consortium has approved the use of EUSA Pharma’s Fotivda (tivozanib) as a first-line treatment for people with …
SMC approves Inlyta
November 13, 2013Sales and Marketing Pfizer, SMC, Sutent, inylta, rcc
Pfizer’s kidney cancer drug Inlyta has been approved by the drugs watchdog in Scotland, making it the only country in …
Double approval for Pfizer cancer drugs
September 6, 2012Sales and Marketing CML, Cancer, Glivec, Pfizer, axitinib, rcc
Two cancer drugs from Pfizer have been approved, one in Europe for kidney cancer and another in the US for …
Torisel-Avastin combo fails in kidney cancer
August 13, 2012Research and Development, Sales and Marketing R&D, Sutent, Torisel, avastin, failure, rcc
Combining Pfizer’s Torisel and Roche’s Avastin does not increase survival rates for advanced kidney cancer patients. This is according to …
Torisel fails in head-to-head study with Nexavar
May 16, 2012Research and Development, Sales and Marketing Bayer, Nexavar, Pfizer, Torisel, inlyta, rcc
Pfizer’s kidney cancer drug Torisel has failed to best Bayer’s Nexavar in a head-to-head trial. The Phase III study was …
FDA approves Pfizer cancer drug Inlyta
January 30, 2012Sales and Marketing Nexavar, Pfizer, Sutent, rcc, renal cell carcinoma
Pfizer’s kidney cancer drug Inlyta has gained US approval for second line treatment for the disease. Inlyta (axitinib) is now …
Pfizer files new kidney cancer drug
June 2, 2011Sales and Marketing Nexavar, Pfizer, rcc
Pfizer has filed its kidney cancer drug axitinib in the EU after impressive head-head- trials with Bayer’s Nexavar. Pfizer is …
Pfizer’s cancer drug meets end points in head-to-head study
May 20, 2011Research and Development, Sales and Marketing Pfizer, axitinib, rcc
Pfizer’s investigational cancer drug axitinib significantly increased survival in kidney cancer patients when compared to Bayer’s standard treatment Nexavar. New …
Astellas to commercialise new kidney cancer drug in Europe
February 21, 2011Sales and Marketing Astellas, Aveo Pharmaceuticals, Cancer, Kidney cancer, rcc, renal cell carcinoma, tivozanib
Astellas and Aveo Pharmaceuticals are to commercialise Aveo’s investigational kidney cancer drug tivozanib in Europe and the US. Aveo is …
GSK’s patient access scheme for Votrient sways NICE
December 24, 2010Sales and Marketing GSK, GlaxoSmithKline, NICE, Votrient, pazopanib, rcc, renal cell carcinoma
NICE has recommended GlaxoSmithKline’s kidney cancer drug Votrient in final draft guidance after the pharma company offered to implement a …
The renal cell carcinoma market: Votrient to challenge Sutent’s lead
November 25, 2010Sales and Marketing GSK, GlaxoSmithKline, Pfizer, Sutent, Votrient, rcc, renal cell carcinoma
After decades of no new medicines emerging to treat renal cell carcinoma, no fewer than five new drugs were approved …
GSK tipped to lead kidney cancer market
July 1, 2010Sales and Marketing Kidney cancer, Patorma, Votrient, rcc
GlaxoSmithKline’s kidney cancer drug Votrient has been forecast as a future leader in a marketplace currently dominated by Pfizer. Analysts …
Latest content
Five Facts about cardiovascular disease
